OR WAIT null SECS
BOSTON-Paratek Pharmaceuticals, Inc., has appointed S. Ken Tanaka, Ph.D, as vice president of research and development. Tanaka's primary responsibilities with Paratek will be to oversee the company's innovative tetracycline and MAR (Multiple Antibiotic Resistance) programs, and will ensure new anti-infective products that address the worldwide problem of bacterial resistance.
Tanaka has 20 years of pharmaceutical industry experience in drug discovery, evaluation, and clinical, regulatory, and market development. His work has focused on oral, parenteral, and aerosolized antibacterial and antifungal drugs for E.R. Squibb and Sons, Inc., (now Bristol Myers-Squibb), Schwarz-Pharma, Abbott Laboratories, and PathoGenesis Corporation.